Nexalin Technology Receives Nasdaq Delisting Warning for Minimum Bid Price Deficiency
Summary
Nexalin Technology, Inc. received a notice from Nasdaq for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day compliance period to avoid potential delisting.
Key Events
-
Nasdaq Deficiency Notice Received
On January 21, 2026, Nexalin Technology, Inc. received a notice from Nasdaq for non-compliance with the $1.00 minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
-
180-Day Compliance Period Initiated
The company has 180 calendar days, until July 20, 2026, to regain compliance by maintaining a closing bid price of $1.00 or more for a minimum of ten consecutive business days.
-
Risk of Delisting and OTC Trading
Failure to regain compliance could result in delisting from Nasdaq, with the company expecting its common stock to then trade on one of the OTC Markets Group's tiered marketplaces.
-
Current Stock Price Below Threshold
The company's common stock currently trades at $0.61, significantly below the required $1.00 minimum bid price.
Analysis
Nexalin Technology, Inc. has received a deficiency letter from Nasdaq for failing to maintain the required $1.00 minimum bid price for its common stock. This notice triggers a 180-calendar-day compliance period, ending July 20, 2026, during which the company must achieve a closing bid price of $1.00 or more for at least ten consecutive business days. Failure to regain compliance could lead to delisting from The Nasdaq Capital Market, potentially forcing the stock to trade on the less liquid OTC Markets Group. The current stock price of $0.61 is significantly below the required threshold, indicating a substantial challenge for the company. While the company states it is not considering a reverse stock split at this time, this situation poses a material risk to its listing status and investor confidence.
At the time of this filing, NXL was trading at $0.61 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $11.3M. The 52-week trading range was $0.54 to $3.87. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.